<p>Supplementary Table 1 Summary of clinical and preclinical studies demonstrating functional and/or structural reversal of proteinuric renal disease with various pharmacologic and nonpharmacologic interventions, excluding endothelin receptor antagonists. First Author Year Disease Study type Intervention/drug type Effects of intervention Comments Reference</p><p>ACE inhibitors Marinides 1990 FSGS (puromycin Preclinical ACE inhibitor Resolution of proteinuria No data on blood Kidney Int nephropathy) and glomerulosclerosis pressure 37: 749–757 Heeg 1991 Diabetic Clinical ACE inhibitor Resolution of proteinuria Antiproteinuric effect was Kidney Int nephropathy independent of systemic 40: 734–41 or renal hemodynamics Ikoma 1991 Renal mass Preclinical ACE inhibitor Reversal of mild or Treatment had a blood- Kidney Int Reduction moderate pressure- lowering effect 40: 195–202 glomerulosclerosis only Zoja 1992 FSGS (MWF) Preclinical ACE inhibitor Resolution of proteinuria Treatment had a blood- Am J Med 92 pressure-lowering effect (Suppl B): 60S– 63S Tanaka 1994 FSGS (puromycin Preclinical ACE inhibitor or Reversal of No data on blood Kidney Int nephropathy) AT1 antagonist glomerulosclerosis pressure 45: 537–543</p><p>Remuzzi 1999 FSGS (MWF) Preclinical ACE inhibitor Resolution of proteinuria Treatment had an Am J Kidney Dis and glomerulosclerosis antihypertensive 34: 626–32 effect Fogo 2001 FSGS (idiopathic Clinical ACE inhibitor or Resolution of proteinuria No data on blood Kidney Int nephrotic (Case steroids/chlorambucil pressure 59: 804–819 syndrome) reports)</p><p>Remuzzi 2002 FSGS (MWF) Preclinical ACE inhibitor plus AT1 Resolution of proteinuria Treatment had an Kidney Int antagonist and glomerulosclerosis antihypertensive 62: 885–894 Inhibition of inflammation effect Remuzzi 2006 FSGS (MWF) Preclinical ACE inhibitor Resolution of proteinuria Treatment had an Kidney Int and glomerulosclerosis antihypertensive 69: 1124–1130 effect</p><p>Angiotensin receptor blockers</p><p>Ma 2000 FSGS (aging) Preclinical AT1 antagonist Resolution of proteinuria Renoprotective effects Kidney Int and glomerulosclerosis were blood- pressure- 58: 2425–2436 independent</p><p>Parving 2001 Diabetic Clinical AT1 antagonist Resolution of proteinuria No effect on blood N Engl J Med nephropathy pressure additional to 345: 870–880 that of antihypertensive therapy</p><p>Brenner 2001 Diabetic Clinical AT1 antagonist Resolution of proteinuria No effect on blood N Engl J Med nephropathy pressure additional to 345: 861–869 that of antihypertensive therapy</p><p>Boffa 2003 Hypertensive Preclinical AT1 antagonist Resolution of proteinuria Renoprotective effects J Am Soc Nephrol nephropathy and glomerulosclerosis were blood- pressure- 14: 1132–1144 (NO deficiency) independent Aldigier 2005 Renal mass Preclinical Spironolactone or Resolution of proteinuria Treatment had an J Am Soc Nephrol Reduction AT1 antagonist and glomerulosclerosis, antihypertensive 16: 3306–3314 and restoration of effect podocytes</p><p>Statins</p><p>Kasiske 1988 Diabetic Preclinical Statin Resolution of proteinuria Antiproteinuric effect was Kidney Int nephropathy independent of 33: 667–672 (Zucker rat) glomerular hemodynamics Abbreviations: ACE, angiotensin-converting enzyme; BMP-7, bone morphogenetic protein-7; BUN, blood urea nitrogen; FSGS, focal-segmental glomerulosclerosis; MWF, Munich Wistar Froemter rat; PAI-1, plasminogen activator inhibitor 1; SHRSP, spontaneously hypertensive stroke-prone rat.</p>